SC-CAR4BRAIN is under clinical development by BrainChild Bio and currently in Phase I for Central Nervous System (CNS) Tumor. According to GlobalData, Phase I drugs for Central Nervous System (CNS) Tumor have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SC-CAR4BRAIN’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SC-CAR4BRAIN overview

SC-CAR4BRAIN is under development for the treatment of pediatric diffuse intrinsic pontine glioma, diffuse midline glioma, and recurrent or refractory central nervous system tumors. The therapeutic candidate is an autologous CD4 plus and CD8 plus T cells lentivirally transduced to express combinations of B7H3, epidermal growth factor receptor 806 (EGFR806), receptor tyrosine protein kinase ERBB 2 (HER2), and interleukin 13 receptor (IL13-zetakine) chimeric antigen receptors (CAR). It is administered through intravenous route.

BrainChild Bio overview

BrainChild Bio is a clinical-stage biotechnology company that focuses on the development of CAR T-cell technology for tumors in the central nervous system (CNS). The company is involved in prioritizing pediatric indications and planning to expand its technology platform to adult brain tumors. It is advancing a next-generation CAR T-cell therapy platform that incorporates synthetic technologies, including multiplex targeting and enhanced potency controls. The company is headquartered in Seattle, Washington, the US.

For a complete picture of SC-CAR4BRAIN’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.